MedTrace Logo

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT04015700 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-05-07

Study results available
· View outcomes & findings →

Summary

This is a single institution, open-label, single arm, study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine in subjects with newly diagnosed, unmethylated glioblastoma.

Conditions

Interventions

BIOLOGICAL

Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics

-The neoantigen DNA vaccines are also known as DNA plasmid vector expressing tumor-specific antigens.

DEVICE

CELLECTRA®2000 EP Device supplied by Geneos Therapeutics

CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.

DRUG

Plasmid encoded IL-12

The INO-9012 vials will be supplied by Geneos Therapeutics

Sponsors & Collaborators

  • Geneos Therapeutics

    collaborator INDUSTRY

  • The Foundation for Barnes-Jewish Hospital

    collaborator OTHER

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Tanner M Johanns, M.D., Ph.D. · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-14
Primary Completion
2022-05-13
Completion
2027-09-03
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04015700 on ClinicalTrials.gov